Hypoxia changes the responses of cancer cells to many chemotherapy agents, resulting in chemoresistance. The underlying molecular mechanism of hypoxia-induced drug resistance remains unclear. Pim-1 is a survival kinase, which phosphorylates Bad at serine 112 to antagonize drug-induced apoptosis. Here we show that hypoxia increases Pim-1 in a hypoxia-inducible factor-1a-independent manner. Inhibition of Pim-1 function by dominantnegative Pim-1 dramatically restores the drug sensitivity to apoptosis induced by chemotherapy under hypoxic conditions in both in vitro and in vivo tumor models. Introduction of siRNAs for Pim-1 also resensitizes cancer cells to chemotherapy drugs under hypoxic conditions, whereas forced overexpression of Pim-1 endows solid tumor cells with resistance to cisplatin, even under normoxia. Dominant-negative Pim-1 prevents a decrease in mitochondrial transmembrane potential in solid tumor cells, which is normally induced by cisplatin (CDDP), followed by the reduced activity of Caspase-3 and Caspase-9, indicating that Pim-1 participates in hypoxia-induced drug resistance through the stabilization of mitochondrial transmembrane potential. Our results demonstrate that Pim-1 is a pivotal regulator involved in hypoxia-induced chemoresistance. Targeting Pim-1 may improve the chemotherapeutic strategy for solid tumors.
Introduction
Hypoxic regions are often present in solid tumors (Vaupel et al., 1991; Koh et al., 1992) . Cancer cells in hypoxic regions present a clinical challenge because they are more resistant to radiotherapy and many chemotherapeutic drugs when compared to cancer cells in normoxic regions (Teicher et al., 1981; Gatenby et al., 1988; Teicher, 1994) . Irregularity in tumor blood flow causes intermittent hypoxia, which promotes solid tumor growth, angiogenesis, radioresistance and chemoresistance (Toffoli and Michiels, 2008) . The biological pathways that are regulated by hypoxia can affect apoptosis, cell cycle, angiogenesis, pH regulation, glucose uptake and glycolysis (Dewhirst et al., 2008) . Hypoxia-induced chemoresistance is an important obstacle to effective cancer chemotherapy.
Hypoxia can upregulate expression of hypoxiainducible genes by regulating the protein level of the a-subunit of the hypoxia-inducible factor (HIF-1a), part of the heterodimeric transcription factor HIF-1. Many of these HIF-1-inducible genes directly or indirectly mediate chemoresistance, such as VEGF, Glut-1, MDR and Bcl-2 (Comerford et al., 2002; Liu et al., 2008) . However, it is unlikely that the cellular response to hypoxia is mediated solely through HIF-1 (Arsham et al., 2004; Mizukami et al., 2004) . PI3K/Akt signaling can induce angiogenesis and oncogenic transition both in HIF-1-dependent and -independent manners (Arsham et al., 2004) . The mechanism of hypoxiamediated chemoresistance, particularly an HIF-1a-independent manner, has not been characterized in detail. Therefore, we searched for novel hypoxiainducible genes with the use of a cDNA microarray system, comparing mRNA expression in cells cultured under hypoxia and normoxia (Niizeki et al., 2002) . We have found that Pim-1 kinase expression is enhanced under hypoxia when compared with normoxia in our preliminary studies (Teh, 2004) .
The oncogene, Pim-1, codes for a serine/threonine kinase (Selten et al., 1986) , which is a member of the Pim kinase family that regulates apoptosis, cell cycle and gene transcription by phosphorylating target proteins such as Bad, p21/waf1, c-Myb and c-Myc Winn et al., 2003; Yan et al., 2003; Aho et al., 2004; Zippo et al., 2004 Zippo et al., , 2007 . Expression of Pim-1 has been shown to correlate significantly with clinical outcome in prostate cancer (Valdman et al., 2004) . Pim-1 is expressed in immature hematopoietic cells, and was first identified as a common integration site in MoMuLV-induced murine T-cell lymphomas (Cuypers et al., 1984) . Pim-1 enhances the survival of hematopoietic cells, in part, through a Bcl-2-dependent pathway (Lilly and Kraft, 1997; Lilly et al., 1999) , and its overexpression leads to an increased incidence of hematopoietic malignancies (van Lohuizen et al., 1989) . Recently it has become evident that Pim kinases may also have important roles outside the hematopoietic system (Eichmann et al., 2000) . The molecular mechanism regulating Pim-1 expression is still not clear and its role of Pim-1 in solid tumor needs to be investigated in detail.
In this study, we investigate the role of Pim-1 in hypoxia-induced chemoresistance in solid malignancies. Here we show that Pim-1 is induced by hypoxia in a HIF-1a-independent manner, and plays an important role in drug resistance. Antagonizing the activity of Pim-1 using a dominant-negative mutant can resensitize cancer cells to drug-induced apoptosis in cell culture and in a xenograft mouse model. Together, our studies indicate that Pim-1 is an important regulator of apoptosis, which mediates chemoresistance under hypoxic conditions. Blocking the upregulation of Pim-1 by hypoxia may yield improved chemotherapies for solid malignancies.
Results

Solid tumor cells are resistant to anticancer drugs under hypoxia
To investigate the impact of hypoxia on the drug sensitivity of cancer cells, we cultured pancreatic cancer cell line PCI-43 under hypoxic or normoxic conditions and monitored cell viability after treatment with gemcitabine and doxorubicin by MTS assay ( Figures  1a and b) . PCI-43 cells were more resistant to gemcitabine (IC 50 : 3.24 mM compared with 0.21 mM) and doxorubicin (IC 50 :1.25 mM compared with 0.29 mM) under hypoxic conditions when compared to normoxia. We also examined cell viability in PCI-43, HeLa and KMP-4 cell lines following treatment with cisplatin (CDDP) by MTS assay (Table 1 ). All three cell lines were more resistant to CDDP under hypoxic conditions compared to normoxic conditions. Next, we examined CDDP-induced apoptosis in a time-dependent manner in PCI-43 cells (Figure 1c; Supplementary Figure 1a) . We found that hypoxia compromised the efficacy of CDDP-mediated apoptosis in these cells when compared to normoxic conditions. We also performed cellcycle analysis by propidium iodide (PI) staining and found that the percentages of sub-G1 cells were decreased under hypoxia versus normoxia (Figure 1d ; Supplementary Figure 1b) . Moreover, we examined CDDP-induced apoptosis by Annexin V staining in three more cancer cell lines (KMP-4, HeLa and PCI-35) under hypoxic or normoxic conditions, and found that CDDP-induced apoptosis was reduced by approximately 50% under hypoxia compared to normoxia (Figure 1e; Supplementary Figure 1c) . Interestingly, hypoxia did not have an impact on anti-Fas-mediated apoptosis in PCI-43 cells as well as in HeLa cells (Supplementary Figure 2) . We also observed that hypoxia conferred resistance to fluorouracil and A23187, which are not substrates of the multiple drug resistance protein (MDR) in PCI-43 cells (Figure 1f ; Supplementary Figure 1d) , as well as in HeLa cells (Figure 1g; Supplementary Figure 1e) . Thus, we conclude that hypoxic conditions lead to chemotherapy resistance.
Hypoxia upregulates Pim-1 in a HIF-1a-independent manner Previously, with the use of a cDNA microarray system, it was found that Pim-1 was expressed at a higher level under hypoxia than under normoxia in pancreatic cancer cell line PCI-10 (Niizeki et al., 2002) . As Pim-1 is an antiapoptotic factor in hematopoietic cells (van Lohuizen et al., 1989; Lilly et al., 1999) , we hypothesized that Pim-1 might also be an antiapoptotic factor induced by hypoxia in solid tumor cells. Indeed, a panel of human cancer cell lines expressed higher levels of Pim-1 protein, as well as mRNA, under hypoxia than under normoxia (Figure 2a) .
We then examined the expression of Bcl-2 family proteins as well as another Pim family protein, Pim-2, under hypoxic and normoxic conditions. Hypoxic conditions did not change the expression level of Bcl-2, Bad, Bid, Bcl-xL, Bax or Pim-2 in PCI-43 cells ( Figure 2b) ; however, Bad protein was phosphorylated after a 1-h exposure to hypoxia. As Bad is a legitimate substrate of Pim-1 and Pim-1 enhances Bcl-2 activity by phosphorylating Bad (Aho et al., 2004) , we hypothesized that Pim-1 might be an earlier hypoxia-inducible target, paralleling Bad phosphorylation under hypoxia. We further characterized the kinetics of induction of Pim-1 by hypoxia and found that the time to maximum induction of Pim-1 (about 1 h) preceded the time to maximum induction of HIF-1a (about 6 h), which is known to upregulate the expression of VEGF and Glut-1 (Figure 2c ). Therefore, it was very unlikely that hypoxia increased Pim-1 via HIF-1a in the same Pim-1 mediates hypoxia-induced chemoresistance J Chen et al P-labeled double stranded oligonucleotide probes (EPO wt33, wild-type probes of proPim-1HRE1, proPim-1HRE2, proPim-1HRE3 and proPim-1HRE4) containing the consensus HIF-1 binding site were incubated with nuclear extracts from PCI-43 cells cultured under normoxia or hypoxia for 16 h and analysed by electrophoretic mobility shift assay (EMSA). For the competition assay (comp), the wild-type (W) or mutant (M) unlabeled oligonucleotide probes were added to nuclear extracts before the addition of labeled probe in normoxia. N: normoxia, H: hypoxia. (f) Luciferase reporter assay for cotransfectants of pGL3-proPim-1 (À1715 to þ 38 bp) with HIF-1a in normoxia (line 2). pGL3-5xHRE and HIF-1a were cotransfected in normoxia as a positive control. pGL3-proPim-1 or pGL3-5xHRE was transfected in hypoxia as another control. A total of 293 cells were cotransfected with indicated plasmids for 24 h. After incubation in normoxia or hypoxia for 16 h, luciferase activity was measured. Fold induction relative to Propim-1 is plotted. Results shown are from three independent experiments.
Pim-1 mediates hypoxia-induced chemoresistance J Chen et al mechanism as typical targets of HIF-1a, such as VEGF and Glut-1. Furthermore, we checked the expression of these proteins in a dominant-negative HIF-1a stable transfectant, dnHIF-1a, which lacks the DNA-binding, transactivation and oxygen dependent degradation domains. dnHIF-1a is reported to act in a dominantnegative manner through the inhibition of functional HIF-1 heterodimer formation without HIF-1a protein level changes (Chen et al., 2003) . Figure 2c also shows that the expression of Pim-1 was still induced by hypoxia in cells transfected with dnHIF-1a whereas the expression of VEGF and Glut-1 were significantly suppressed by dnHIF-1a. Also, we found that Pim-1 is still induced under hypoxic condition even in HIF-1a knockdown HCT116 and HeLa cells ( Figure 2d ). Taken together, these results suggest that Pim-1 is regulated by hypoxia in a HIF-1-independent manner. To further confirm whether hypoxia activated Pim-1 transcription through interaction of HIF-1 with the Pim-1 promoter, we employed the electrophoretic mobility shift assay (EMSA). The Pim-1 promoter contains four putative hypoxia response elements (HRE regions (DNA consensus binding motif: 5 0 -RCGTG-3 0 ); Semenza, 1999; Comerford et al., 2002 ) located at positions: À315BÀ306 (HRE1), À768B À759 (HRE2), À874BÀ865 (HRE3) and À965BÀ956 (HRE4; Supplementary Figure 3 ). Although HIF-1 did not bind to any of the four Pim-1 promoter probes (Figure 2e ), more HIF-1 bound to the positive control EPOwt33 probe under hypoxia than under normoxia, and this increase in binding was reversible by competition with unlabeled EPOwt33 probe. These results suggest that the putative HIF-1 binding sites in the Pim-1 promoter region are not being utilized by HIF-1.
Next, we cloned the Pim-1 promoter (À1715 to þ 38 bp) into a luciferase reporter vector, pGL3-basic plasmid. As shown in Figure 2f , no increase in luciferase activity was found in 293 cells cotransfected with pGL3-proPim-1 and HIF-1a plasmids under normoxia, when compared to those transfected with pGL3-proPim-1 alone. However, in the positive control, luciferase activity was increased in cells cotransfected with pGL3-5xHRE and HIF-1a plasmids under normoxia. Interestingly, luciferase activity was increased in the cells transfected with pGL3-proPim-1 under hypoxia, suggesting that hypoxia can enhance Pim-1 expression in a HIF-1-independent manner, probably through other hypoxic pathways.
Dominant-negative Pim-1 sensitizes cells to apoptosis
To define the role of Pim-1 in chemoresistance under hypoxia, we antagonized the function of Pim-1 by transfecting PCI-43 cells with dominant-negative Pim-1 (dnPim-1). dnPim-1, which inhibits the function of wildtype Pim-1 (Lilly et al., 1999) , lacks a kinase activation domain (1-81aa; Figure 3a) . In Figure 3b , we evaluated the expression of dnPim-1 in three stable dnPim-1-transfectants. As Pim-1 is a survival kinase that is known to phosphorylate Bad at ser112, which is an important inactivation site, thus promoting cell survival, we confirmed the antagonistic effect of dnPim-1 on Pim-1-mediated phosphorylation of Bad (Figure 3c ). The phosphorylation of Bad at ser112 was also increased under hypoxia in vector control but not in dnPim-1 transfectants. There were no changes in the total protein levels of Bad (Figure 3c ). These results indicate that hypoxia increases Pim-1, which phosphorylates and inactivates Bad to inhibit apoptosis. Next, we examined the sensitivity of dnPim-1 transfectants to apoptosis. As expected, dnPim-1 transfectants and vector control cells had small percentages of apoptotic cells in the absence of drug treatment (Figure 3d; Supplementary Figure 4) . Hypoxia inhibited CDDP-induced apoptosis in vectortransfected control cells (V3), but this hypoxia-induced chemoresistance was no longer present in dnPim-1 transfectants (dnP3 and dnP4; Figure 3e To further confirm the role of Pim-1 in hypoxiainduced chemoresistance, we also employed molecular methods to knockdown Pim-1 levels. Under hypoxia, siRNAs for Pim-1 effectively suppressed Pim-1 protein expression in PCI-43 cells (Figure 4a ), and siRNA suppression of Pim-1 restored sensitivity to CDDP (Figures 4b and c) . Conversely, we established Pim-1-overexpressing stable transfectant PCI-43 cells ( Figure 4d ) and found that overexpression of Pim-1 rendered the cells resistant to CDDP under normoxia (Figures 4e and f) , underscoring Pim-1's role as a mediator of chemoresistance.
In vivo sensitivity to CDDP in dominant-negative Pim-1 transfectants To examine the sensitivity of dnPim-1 transfectants to CDDP in vivo, we used Tet-On dominant-negative transfectants of HeLa cells, which expressed dnPim-1 protein in the presence of doxycycline (Figure 5a ). Administration of doxycycline together with CDDP completely suppressed the growth of the Tet-On dnPim-1-transfectants in a SCID mouse xenograft model. In contrast, CDDP could only slightly suppress the growth of the transfectants when dnPim-1 was not induced (Figure 5b ). As most solid tumors contain hypoxic regions, these results suggest that Pim-1 induced by hypoxia may be responsible for the intrinsic resistance to anticancer drugs in solid tumor cells and that the suppression of Pim-1 function could be helpful for the chemotherapy of solid tumors.
Pim-1 induces resistance to anticancer drugs through the stabilization of mitochondrial transmembrane potential As Pim-1 had no effect on apoptosis induced by antiFas antibody (Figure 3f ), we hypothesized that Pim-1 might induce resistance to anticancer drugs by inhibiting the intrinsic mitochondrial apoptosis pathway through stabilization of mitochondrial transmembrane potential (MTP). We used tetramethylrhodamine, ethylester, perchlorate (TMRE; an indicator of MTP) to measure MTP by FACS (Figures 6a and b) . We found that the MTP in vector control cells after exposure to CDDP for 48 h was higher under hypoxia than under normoxia (Figure 6a , peak fluorescence indicated by arrows). By contrast, there is no difference in MTP in dnPim-1 transfectants between hypoxia and normoxia at the same time point. Consistent with the above findings, CDDP-induced Caspase-9 and Caspase-3 activities under normoxia were compromised by hypoxia in control cells (Figures 6c and d) . As for the dnPim-1 transfectant, Caspase-9 and Caspase-3 activities were increased by CDDP regardless of hypoxia or normoxia (Figures 6c and d) suggesting again that inhibiting Pim-1 activity resensitized cells to chemotherapy. Note that the anti-Fas antibody had no impact on Caspase-9 and Caspase-3 activities in either control cells or dnPim-1 transfectants (Figures 6c and d) . The specificities of the Caspase-9 and Caspase-3 assays were confirmed using Z-LEHD-FMK (Caspase-9 inhibitor) and Ac-DEVD-CHO (Caspase-3 inhibitor), respectively. CDDP did not increase the activity of Caspase-8 whereas anti-Fas Ab increased Caspase-8 activity regardless of normoxia or hypoxia (Figure 6e ). Ac-IETD-CHO (Caspase-8 inhibitor) was used to confirm the specificity of the Pim-1 mediates hypoxia-induced chemoresistance J Chen et al
Caspase-8 assay. Together, these data indicate that Pim-1 mediated hypoxia-induced chemoresistance by affecting MTP and regulating the activities of Caspase-9 and Caspase-3.
Discussion
In this study we show that hypoxia causes resistance to chemotherapy in a variety of cancer cells. The underlying molecular mechanism of hypoxia-induced chemoresistance has not been previously characterized in detail. Here, we show that Pim-1 can be induced by hypoxia and it plays an important role in drug resistance to CDDP, gemcitabine and fluorouracil. The phosphorylation of Bad at ser112 by Pim-1 connects hypoxia to the inhibition of apoptosis, offering a novel mechanism as to how hypoxia contributes to compromised drug therapy response. HIF-1 plays an important role in hypoxia-induced gene expression. Scanning the 5 0 -promoter region of Pim-1 for the consensus sequence of the HIF-1 response Pim-1 mediates hypoxia-induced chemoresistance J Chen et al element (HRE) has revealed several potential binding sites for HIF-1. We have tested the possibility that HIF-1 can regulate the expression of Pim-1 by binding to these putative HREs and found this is not the case. Three lines of evidence demonstrate that the activity of HIF-1 is not a critical regulator of Pim-1. First, HIF-1 does not bind to the putative HRE sites in the Pim-1 promoter region as assayed by EMSA (Figure 2e) . Second, HIF1a cannot enhance luciferase activity in pGL3-proPim-1 reporter, which contains the Pim-1 promoter sequence (À1715 to þ 38 bp; Figure 2f ). Last, in dnHIF-1a as well as in HIF-1a knockdown cells, inhibition of HIF-1a expression and activity cannot block the increase of Pim-1 protein level under hypoxia (Figures 2c and d) . These results strongly suggest that the mechanism of upregulation of Pim-1 transcription is independent of HIF-1a. As some previous studies demonstrated that AP-1 and nuclear factor-kB were involved in the upregulation of various hypoxia-inducible genes (Koong et al., 1994; Bandyopadhyay et al., 1995) , it is possible that these transcription factors may be involved in the regulation of Pim-1 under hypoxia. Moreover, rapid and prominent elevation of the Pim-1 protein, earlier than HIF-1 appearance, after exposure to hypoxia (Figure 2b ), favors the notion that the expression of Pim-1 protein may be regulated posttranscriptionally, in a HIF-1-independent manner (Qian et al., 2005) .
Pim-1 protein is induced earlier than other hypoxiainduced factors, suggesting that Pim-1 displays its role in survival of solid tumor cells following exposure to acute, as well as, chronic hypoxia. Most other hypoxiainducible factors, such as, VEGF, glucose transporters and MDR1, are induced in an HIF-1-dependent manner when exposed to chronic hypoxia. It is described that tumor hypoxia develops as a result of two independent phenomena: chronic hypoxia caused by limitation of oxygen diffusion; transient hypoxia caused by instability of microvessel flow (Cardenas-Navia et al., 2004) . In our in vivo result, a remarkable regression of tumors ( Figure 5 ) obtained by the combination of CDDP and dnPim-1, can be explained by our recent observation that dnPim-1 also has an impact on tumor angiogenesis by significantly decreasing CD31 expression in tumor tissue (Chen et al., 2009) . Few studies have reported on the role of Pim-1 in vasculogenesis or angiogenesis. These results, in combination with a recent report that demonstrated Pim-1 is required for VEGF-A-dependent proliferation and migration of endothelial cells (Zippo et al., 2004) , implies that Pim-1 may modulate VEGFinduced angiogenesis.
Pim-1 is a survival kinase and phosphorylates many targets that regulate apoptosis, cell cycle and gene transcription. How Pim-1 exerts its influence on cells in preventing them from undergoing apoptosis remains unclear. Apoptosis is accompanied by a variety of mitochondrial dysfunctions. For instance, loss of MTP and production of reactive oxygen species (ROS) are early events in cells destined to undergo apoptosis (Zamzami et al., 1995) . Pim-1 is considered to inhibit the production of ROS indirectly, during anticancer druginduced apoptosis (Lilly et al., 1999) , resulting in the restoration of MTP. Bad is a legitimate substrate of Pim-1, and Pim-1 can enhance Bcl-2 activity by phosphorylating Bad. In this study, Bad was phosphorylated under hypoxia, whereas no phosphorylation of Bad was observed in dnPim-1 transfectants under normoxia or hypoxia. These findings suggest that the phosphorylation of Bad may be responsible for the drug sensitivity decrease induced by overexpression of Pim-1 under hypoxic conditions. To determine whether the hypoxia-Pim-1 axis is also regulating the death receptor pathway to affect hypoxia-mediated drug resistance, we checked the expression of Bid, which is a Bcl-2 family protein, interposed between the death receptor pathway (Fas and tumor necrosis factor) and the mitochondrial pathway in the vast majority of Fas-sensitive cells. Although Bid is known to translocate itself to the mitochondria, causing proapoptotic changes (Luo et al., 1998) . We found that Bid was not involved under hypoxia (Figure 2b) . Also, our observations showed that anti-Fas antibody induction of Caspase-8 and the resulting apoptosis were not affected by hypoxia (Figure 6d ). Taken together, these results suggest that hypoxia-induced Pim-1 signaling is related to mitochondrial dysfunction (loss of MTP) but independent of the Fas-Caspase-8-Bid pathway. Given that hypoxia is associated with chemoresistance and that hypoxia can enhance Pim-1 expression, it is conceivable that Pim-1 would be an ideal target for rational cancer therapy. An important new concept advanced here is that antagonizing Pim-1 activity can sensitize cancer cells to chemotherapy drug and justifies (c) dnPim-1 transfectants under normoxic or hypoxic conditions with the indicated treatments were assayed for Caspase-9 activity via spectrofluorometer. (d) Caspase-3 activity was assayed as described in (c). (e) Caspase-8 activity was assayed as described in (c). The activities of Caspase-3, Caspase-8 and Caspase-9 were inhibited with Ac-DEVD-CHO, Ac-IETD-CHO and Z-LEHD-FMK, respectively. N: normoxia, H: hypoxia.
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Pim-1 as an important molecular target for developing specific small molecule inhibitors for combination chemotherapy, and such drug development effort has begun (Pierce et al., 2008) .
Materials and methods
Cell lines and reagents
Pancreatic ductal adenocarcinoma cell lines (PCI-10, PCI-35, PCI-43 cells and KMP-4) were kindly supplied by Dr Hiroshi Ishikura (The First Department of Pathology, Hokkaido University School of Medicine) and Dr Yutaka Shimada (Department of Surgery and Surgical Basic Science Graduate School of Medicine, Kyoto University). dnHIF-1a transfectants were established by Chen et al. (2003) . Annexin-V-FLUOS staining kit was purchased from Japan Roche Diagnostic Co. Ltd (Tokyo, Japan). Small interfering RNAs (siRNAs) for Pim-1 were synthesized with the Silencer siRNA Construction kit (Ambion; Cat. 1620). Sequences for Pim-1 siRNA are shown in Supplementary Table 1. siRNAs for HIF-1a (ON-TARGETplus SMARTpool siRNA) and siRNA control (ON-TARGETplus nontargeting Pool), were purchased from Thermo Scientific Dharmacon (Chicago, IL, USA). Sequences for HIF-1a siRNA are shown in Supplementary Table 1 . Caspase activity assay kits for Caspase-3, Caspase-8 and Caspase-9 were purchased from BD Biosciences (San Jose, CA, USA). Inhibitors of Caspase-3, Caspase-8 and Caspase-9 (Ac-DEVD-CHO, Ac-IETD-CHO, Z-LEHD-FMK) were purchased from BD Biosciences. Carbonylcyanide m-chlorophenylhydrazone (CCCP) was purchased from Sigma-Aldrich Japan (Tokyo, Japan).
Sensitivity to anticancer drugs
Sensitivity of tumor cell lines to anticancer drugs was determined by a colorimetric MTS assay according to the manufacturer's instructions (Cell Titer 96 Aqueous Nonradioactive Cell Proliferation Assay; Promega, Madison, WI, USA). A total of 2 Â 10 3 cells were incubated with different doses of anticancer drugs for 48 h under normoxia (20% O 2 /5% CO 2 ) or hypoxia (1% O 2 /5% CO 2 ). Incubation under hypoxia was done in a hypoxic chamber gassed with 95% N 2 and 5% CO 2 (Wakenyaku Co. Ltd, Tokyo, Japan). After incubation, the cells were incubated for 3 h with MTS solution. Subsequently, the absorbance was measured at 490 nm on an ELISA reader (BioRad Model 550).
FACS analysis
Sensitivity of tumor cell lines to apoptosis was determined by two-color analysis using PI and FITC-conjugated antiannexin V according to the manufacturer's instructions. After incubation with or without CDDP, at 25 mM for 48 h, under normoxia or hypoxia, the cells were stained with PI and FITCconjugated antiannexin V and analysed with a FACScalibur flow cytometer (Becton Dickinson, Mountain View, CA, USA).
Cell-cycle analysis was performed with PI staining. After incubation with or without CDDP, at 50 mM for 72 h, under normoxia or hypoxia, the cells were washed twice with phosphate-buffered saline (PBS), harvested by trypsinization, fixed with ice-cold 70% ethanol, treated with RNaseA (0.25 mg/ml) and stained with PI (0.02 mg/ml). Analyses were performed with a FACScalibur flow cytometer (Becton Dickinson).
Western blot analysis
Total proteins were separated on 4-12% gradient polyacrylamide gels and electrotransferred to polyvinylidene difluoride membranes. Membranes were incubated with anti-Pim-1 antibody (Transduction Laboratories Inc., Lexington, KY, USA), anti-Pim-2 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-Bcl-2 antibody (Pharmingen Inc., San Diego, CA, USA), anti-Bax antibody (Pharmingen), anti-Bcl-xL antibody (Cell Signaling Technology Inc.), anti-Bid antibody (Santa Cruz Biotechnology), anti-Bad antibody (Cell Signaling Technology), anti-Phospho-Bad (Ser112) antibody (Cell Signaling Technology), anti-HIF-1a antibody (Santa Cruz Biotechnology, Danvers, MA, USA), anti-VEGF antibody (Upstate Biotechnology Inc., Lake Placid, NY, USA), anti-Glut-1 antibody (Immuno-Biological Laboratories Inc., Gunma, Japan), anti-HIF-1a antibody (Novus Biologicals Inc., Littleton, CO, USA), anti-HA antibody (Santa Cruz Biotechnology), anti-FLAG M2 monoclonal antibody (Sigma, St Louis, MO, USA) or anti-actin antibody (Santa Cruz Biotechnology).
Northern blot analysis
Northern blot analysis was performed by the method described previously (Chen et al., 2003) . Total RNA (25 mg) was separated by electrophoresis in 1% denaturing formaldehydeagarose gels. The RNA was transferred to a nylon membrane (Hybond; Amersham, Pittsburgh, PA, USA) by capillary elution overnight and UV cross-linked. The membrane was hybridized overnight at 42 1C with the cDNA probe labeled with 32 P by the use of a random primer DNA labeling kit (Takara Biomedicals, Tokyo, Japan) for Pim-1. Probes for Pim-1 were obtained by PCR amplification with the use of primers as follows: Pim-1 forward, 5 0 -ggttggatgctcttgtccaa-3 0 ; reverse, 5 0 -ccttccagaagtcttctat-3 0 .
Quantitative PCR Total RNA was extracted with the use of TRIZOL reagent according to the manufacturer's instructions. Reverse Transcription were performed by using SuperScriptn III FirstStrand kit (Invitrogen, Carlsbad, CA, USA). Each cDNA (10 ng) was amplified in triplicate with iQ SYBR Green Supermix PCR kit (Bio-Rad) for 40 cycles on a Bio-Rad system (iCycler Thermal Cycler). Sequences for Pim-1 primer and b-actin primers are shown in Supplementary Table 1 .
Electrophoretic mobility shift assay EMSA was performed according to the previously described method (Chen et al., 2003) . After 16 h incubation of PCI-43 cells in hypoxia and normoxia, nuclear extracts were obtained. Double-stranded HIF-1-specific EPO wt33 oligonucleotide probe containing two HIF-1-binding sites in tandem (5 0 -gccctacgtgctgtctcacacagcctgtctga-3 0 and 5 0 -gtcagacaggctgtg gagacagcacgtaggg-3 0 ) were end-labeled with [ 32 P] dCTP by Klenow fragment. Nuclear extract (3 mg) was incubated with a 300 fmol probe in 30 ml binding buffer (10 mM HEPES, pH 7.8, 50 mM KCl, 1 mM ethylenediaminetetraacetic acid, 5 mM MgCl 2 , 10% v/v glycerol, and 2 mg of poly-dI-dC) for 20 min at room temperature. For the competition assay, a 50-fold molar excess of unlabeled oligonucleotide probe was added to nuclear extracts for 15 min before the addition of labeled probe. Sequences for synthetic oligonucleotide probes are shown in Supplementary Table 2.
Luciferase reporter gene assay The Pim-1 promoter region was amplified by PCR with primers, 5 0 -GCTGTATGACCCTGTGCCAT-3 0 sense and Pim-1 mediates hypoxia-induced chemoresistance J Chen et al 5 0 -CTGCAGCAGACGCCCGGCTC-3 0 antisense, and ligated into pGL3-basic vector. A total of 293 cells were seeded in 24-well plates at 5 Â 10 4 cells per well overnight, and then were cotransfected with plasmids pGL3-proPim-1 (0.5 mg) expressing the sequence corresponding to proPim-1 (À1715 to þ 38 bp) of the Pim-1 promoter, or pGL3-5 Â HRE (0.5 mg) which included five tandem repeats of the erythropoietin gene HRE sequence (5 0 -CGCCCTACGTGCTGTCTCACACAGC CTGTCTGA-3 0 ) and pcDNA3.1-HIF-1a (0.5 mg) expression vector with the Lipofectamine 2000 transfection kit. The Rapid Response phRL-CMV Vector (Catalog No. E6271; Promega; 50 ng) was transfected simultaneously and used as an internal transfection control. In subsets of experiments, cells were transfected with empty pGL3-basic vector (Promega) to control background luciferase activity. After transfection, cells were subjected to hypoxia or normoxia for 16 h. Luciferase activity was assessed using a Dual-Luciferase Reporter assay system (Promega) and Lumat LB 9506 luminometer (Berthold, Oak Ridge, TN, USA) according to the manufacturer's instructions.
Establishment of dominant-negative Pim-1 transfectants cDNA for dnPim-1, which lacks the kinase activation domain (Lilly et al., 1999) , was amplified from reverse transcription products of mRNAs purified from PCI-10 cells and cloned into PCR4-TOPO. Plasmids were sequenced with a DyeDeoxy Terminator kit (Perkin-Elmer, Urayasu, Japan) on an ABI 377 automated sequencer (Applied Biosystems, Urayasu, Japan) according to the manufacturer's protocol. Cloned fragments were ligated into PcDNA3.1 þ (Invitrogen). PCI-43 cells were transfected with the expression vector with the use of Lipofectamine (Life Technologies, Tokyo, Japan). Transfectants were cloned by a limiting dilution method following selection with G-418 (1200 mg/ml). Transfectants were maintained in the presence of 600 mg/ml of G-418. Sequences of PCR primers are shown in Supplementary Table 1.
Mitochondrial membrane potential and caspase activity assay The mitochondria-specific dye, TMRE (200 nM; Molecular Probes, Carlsbad, CA, USA) was added during the last 30 min of treatment with hypoxia or normoxia in PCI-43 cells. The medium was transferred into a 75-mm Falcon polystyrene tube and the adherent cells were trypsinized and collected into the same tube. After washing with PBS, the cells were analysed by the use of a FACScan flow cytometer (Becton Dickinson, Sunnyvale, CA, USA) for mitochondrial uptake. Untreated cells and cells treated with 50 mM CCCP were used as negative controls and positive controls, respectively. Caspase activities were determined according to the manufacturer's instructions. dnPim-1 transfectants and vector controls were treated with CDDP under normoxia or hypoxia for 48 h, and cells lysed. Cell lysate (50 ml) was incubated with 15 ml of each caspase fluorogenic substrate (DEVD-AFC for Caspase-3; IETD-AFC for Caspase-8; LEHD-AMC for Caspase-9) for 1 h at 37 1C. Subsequently, the amount of AFC or AMC liberated from substrates was measured by a spectrofluorometer. The inhibitors of Caspase-3, Caspase-8 and Caspase-9, (Ac-DEVD-CHO; Ac-IETD-CHO; Z-LEHD-FMK) were added in each mixture as controls.
Preparation of a HeLa cell line expressing dnPim-1 in the presence of doxycycline A tetracycline-inducible expression system and the HeLa/ Tet-On cell line, a HeLa clone expressing a reverse tetracycline-controlled transactivator, were purchased from BD Biosciences Clontech (Palo Alto, CA, USA). HeLa Tet-On cells were transfected with pTRE/dnPim-1 and PTK-Hyg, a plasmid expressing the hygromycin resistance gene (BD Biosciences Clontech). The cells were cultured for more than 4 weeks in medium containing hygromycin (200 mg/ml) to obtain stable transfectants.
In vivo tumorigenicity SCID mice were housed in AAALAC approved barrier facilities on a 12-h light/dark cycle, with food and water ad libitum. The mice were treated under approved protocols in compliance with the animal care and use guidelines in accordance with international standards including the NIH of the United States of America. Five million cells of dnPim-1 transfectants were injected subcutaneously into the right flank of each mouse (n ¼ 5, in each group). Tumor formation was observed every 3 days for 3 weeks after inoculation. Tumor volumes were measured with this formula: tumor volume ¼ 0.5 Â ab 2 (a, major axis; b, minor axis; Yoshida et al., 1989) . Body weight, feeding behavior and motor activity were monitored thrice weekly as indicators of general health. Animals with the following conditions were killed: >10% weight loss, motor retardation, inability to obtain food or water, ruffled hair or largest diameter of the tumor >15 mm.
Statistical analysis
All statistical analyses except the analysis of tumor sizes in the xenograft study were performed using an unpaired Student's t-test for two groups and one-way analysis of variance with post hoc intergroup comparisons using Tukey test for multiple groups. The xenograft data were analysed by linear mixed models (SPSS for Windows, version 12.0; SPSS Inc., Chicago, IL, USA) with comparisons of fixed effects using the restricted maximum likelihood method.
Abbreviations CCCP, carbonylcyanide m-chlorophenylhydrazone; CDDP, cisplatin; dnPim-1, dominant-negative Pim-1; HIF-1, hypoxiainducible factor-1; HRE, hypoxia response element; MTP, mitochondrial transmembrane potential; TMRE, tetramethylrhodamine, ethylester, perchlorate.
